Davis W M, Waters I W
University of Mississippi, University 38677, USA.
Med Hypotheses. 1997 Dec;49(6):509-12. doi: 10.1016/s0306-9877(97)90070-0.
Clinical observations over the past 15 years incriminated first fenfluramine and recently dexfenfluramine in the provocation of primary pulmonary hypertension. Limited animal toxicology data tend to support this inference. The basis for respiratory pathology of high-altitude pulmonary malfunction, which reaches its maximal level in high-altitude pulmonary edema, evolves from and depends upon the occurrence of pulmonary hypertension. For this reason we hypothesize that high altitude and these two anorexic medications constitute a potentially synergistic combination, of which physicians treating patients for high-altitude illness, as well as those prescribing the drugs, should be aware.
过去15年的临床观察表明，首先是芬氟拉明，最近是右芬氟拉明，引发了原发性肺动脉高压。有限的动物毒理学数据倾向于支持这一推断。高原肺功能障碍的呼吸病理学基础在高原肺水肿中达到最高水平，它由肺动脉高压发展而来并依赖于肺动脉高压的发生。因此，我们推测高原环境与这两种厌食药物构成了一种潜在的协同组合，治疗高原病患者的医生以及开这些药物的医生都应该对此有所了解。
